Estrella Immunopharma, Inc.
ESLA
$1.15
$0.021.77%
NASDAQ
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Net Income | -26.41% | -47.65% | -53.10% | -65.16% | -72.07% |
| Total Depreciation and Amortization | -- | -- | -- | -- | -- |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 27.39% | 52.02% | -- | -37.18% | -54.41% |
| Change in Net Operating Assets | -25.58% | 1,269.00% | 209.07% | 173.67% | 154.68% |
| Cash from Operations | -107.12% | 76.63% | 86.10% | 75.14% | 75.53% |
| Capital Expenditure | -- | -- | -- | -- | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | -- |
| Cash from Investing | -- | -- | -- | -- | -100.00% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 12,981.76% | 2,918.87% | -- | -85.71% | -99.21% |
| Repurchase of Common Stock | 100.00% | 94.81% | 98.32% | 95.50% | 90.03% |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | 96.54% | 94.99% | -- |
| Cash from Financing | 2,290.34% | 560.36% | 131.52% | -91.05% | -103.33% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 134.97% | 105.75% | 99.16% | -268.95% | -308.18% |